– UK, London – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, today announced the appointment of current CFOO, Dr. Young Kwon (Ph.D.) to its Board of Directors as new CEO, succeeding Dr. Doug Treco who resigned.
“We are delighted that Young will lead our Company and join our Board. He has established himself as an outstanding leader and we are thrilled that he will be driving the Company forward during this exciting phase of growth. In addition to building transformative biotech companies, Young’s track record working with and developing talented teams will build on and shape Alchemab’s diverse, ambitious and unique culture. As the Company continues to grow its footprint in the U.S. and the U.K., we look forward to working with Young to advance our novel programs to the clinic and build out our highly differentiated platform.” said Board Chairman, Houman Ashrafian.
About Dr. Young T. Kwon
Dr. Kwon has served as Alchemab’s CFOO since November 2021. Dr. Kwon previously served as CFBO of Momenta Pharmaceuticals until its acquisition by Johnson & Johnson in October 2020. Before Momenta, Dr. Kwon was a business development professional at Biogen and worked at the venture capital firm Advanced Technology Ventures, investing in early-stage biotech and medical device companies.
“I am excited by Alchemab’s potential,” said Dr. Kwon, “Over the last six months I have seen how combining experienced drug discovery capabilities with the latest computational approaches pave a new era in therapeutics discovery. I am grateful to Doug for his support and guidance and I look forward to the challenge of building upon the outstanding foundations that he has established.”
Dr. Kwon received a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University.
About Alchemab
Alchemab has developed a highly differentiated platform which enables the identification of novel drug targets, therapeutics, and patient stratification tools by analysis of patient antibody repertoires. The platform uses well-defined patient samples, deep B cell sequencing, and computational analysis to identify convergent protective antibody responses among individuals that are susceptible but resilient to specific diseases.
Alchemab is building a broad pipeline of protective therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology. The highly specialized patient samples that power Alchemab’s platform are made available through valued partnerships and collaborations with patient representative groups, biobanks, industry partners, and academic institutions.
For more information: https://www.alchemab.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.